Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3761MR)

This product GTTS-WQ3761MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3761MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14010MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ6419MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ8719MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ1567MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ11636MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ9322MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ13469MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ1938MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW